We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.
BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (βTempestβ or the βCompanyβ), a clinical-stage biotechnology company developing first-in-classi...
BRISBANE, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...
BRISBANE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
BRISBANE, Calif., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
BRISBANE, Calif., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...
BRISBANE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0823 | 8.68418275826 | 0.9477 | 1.045 | 0.8637 | 3345633 | 0.95052217 | CS |
4 | -0.36 | -25.8992805755 | 1.39 | 1.59 | 0.8637 | 8194076 | 1.08925282 | CS |
12 | -0.06 | -5.50458715596 | 1.09 | 2.18 | 0.8637 | 4905785 | 1.27510689 | CS |
26 | -2.72 | -72.5333333333 | 3.75 | 3.79 | 0.8637 | 2865030 | 1.42365171 | CS |
52 | -2.69 | -72.311827957 | 3.72 | 6 | 0.8637 | 2239799 | 2.2656945 | CS |
156 | -10.92 | -91.3807531381 | 11.95 | 12.3 | 0.17 | 1584104 | 4.40712232 | CS |
260 | -12.78 | -92.5416364953 | 13.81 | 41 | 0.17 | 1460178 | 4.93238221 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions